medigraphic.com

2019, Number 1

<< Back Next >>

Rev Clin Esc Med 2019; 9 (1)

Penfigo Vulgar y Foliaceo: Una revisión bibliográfica

Carvajal EM, Jiménez TI, Francesa BG

Language: Spanish
References: 22
Page: 48-55
PDF size: 265.89 Kb.


ABSTRACT

For this article, a bibliographic review of pemphigus has been made, with emphasis on the types vulgaris and foliaceus, using several databases such as: AAD, UptoDate, JAAD, NEJM, ScieLo, The Bmj,IntraMed, BINASSS, MedScape; with the objective of updating the information on this disease, in terms of: epidemiology, etiopathology, most frequent signs and symptoms, most commonly used diagnostic methods and treatment.
It is an autoimmune dermatological disease, its main lesion is vesicular-bullous with a background that could be erythematous or not. In most of the investigations, there is talk of no predilection based on gender, however, there are other studies that contradict it. Its two main types are vulgaris and foliaceus, which will be discussed in this review. In Costa Rica, it is one of the autoimmune bullous diseases with the highest percentage of deaths. The diagnosis is based in the clinical findings as well as in the histologic and immunologic findings as confirmatory measurres. The treatment consists mainly in systemic corticosteroids, which can be used in combination with immunosuppressants or other drugs such as rituximab, in order to reduce the dosage of corticosteroids and thus their common adverse effects.


REFERENCES

  1. Valencia-Ocampo O Velásquez-Lopera M. Inmunopatogenia del pénfigo vulgar y el pénfigo foliáceo. Iatreia. 2011; 24 (3): 272-286.

  2. Herrera-López I Miranda-Tarrago J. Pénfigo vulgar, criterios actuales. Revista Habanera de Ciencias Médicas. 2009; 8 (5): 45-51.

  3. Sanchez-Pérez J García-Diez A. Pénfigo. Actas Dermo-Sifiliograficas. 2005; 96 (6): 329-356.

  4. Stanley J Amagai M. Pemphigus, bullous impetigo and the Staphylococcal scalded-skin syndrome. N Engl J Med. 2006; 355: 1800-1810.

  5. Chinchilla-González A. Epidemiologia de enfermedades ampollosas autoinmunitarias en Costa Rica. Revista Médica de Costa Rica y Centroamérica. 2002; 69 (561): 153-159.

  6. Hertl M Sitaru C. Pathogenesis, clinical manifestations, and diagnosis of pemphigus. Up to Date. 2018.

  7. Hertl M Geller S. Initial management of pemphigus vulgaris and pemphigus foliaceus. Up to Date. 2017. Disponible en: https://www.uptodate.com/contents/initialmanagement- of-pemphigus-vulgaris-and-pemphigus-folia ceus?search=pemphigus&source=search_result&selectedT itle=2~114&usage_type=default&display_rank=2.

  8. Tamgadge S Tamgadge A Bhatt D Bhalerao S Pereira T. Pemphigus vulgaris. Contemporary Clinical Dentistry. 2011; 2 (2): 134-137.

  9. Aldama A Aquino N. Pénfigo. Tendencias en Medicina. 2016; 11 (11): 102-106.

  10. Sirois D Leigh J Sollecito T. Oral pemphigus vulgaris preceding cutaneous lesions: recognition and diagnosis. J Am Dent Assoc. 2000; 131: 1156-1160.

  11. Castellanos-Iñiguez A Guevara-Gutiérrez E. Pénfigo vulgar. Dermatología Revista Mexicana. 2011; 55 (2): 73-83.

  12. Huang A Madan R Levitt J. Future therapies for pemphigus vulgaris: Rituximab and beyond. J Am Acad Dermatol. 2016; 74 (4): 746-753.

  13. Peña-Ortiz J Romero-Álvarez J Trujillo-Padilla S. Abordaje terapéutico dermatológico ambulatorio del pénfigo vulgar en adultos. Instituto Mexicano de Seguro Social. México D.F. 2013.

  14. Atzmony L Hodak E Leshem Y et al. The role of adjuvant therapy in pemphigus: A systemic review and meta-analysis. J Am Acad Dermatol. 2015; 73 (2): 264-271

  15. Gregoriou S Efthymiou O Stefanaki C Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clinical, Cosmetic and Investigation Dermatology. 2015; 8: 521-527.

  16. Doukaki S Platamone A Alaimo R Bongiorno M. Mycophenolate mofetil and enteric coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus. Journal of Dermatological treatment. 2015; 26 (1): 67-72.

  17. Kayani M Aslam A. Bullous pemphigoid and pemphigus vulgaris. BMJ. 2017; 357: j2169.

  18. Hertl M Eming R. Management of refractory pemphigus vulgaris and pemphigus foliaceus. Up to Date. 2017.

  19. Diaz L. Rituximab and pemphigus-A therapeutic advance. N Engl J Med. 2007; 357 (6): 605-607

  20. McCarty M Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol. 2014; 71 (3): 475-479.

  21. Korman N. Pemphigus. J Am Acad Dermatol. 1988; 18 (6): 1219-1238.

  22. Matos-Cruz R Bascones-Martinez A. Pénfigo: Una revisión de la literatura. Avances en odontoestomatología. 2009; 25 (2): 67-82.




2020     |     www.medigraphic.com